What's in BRIM Biotechnology Inc.'s pipeline?

BRIM Biotechnology Inc. has 5 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 4 in Phase 2, 0 in Phase 1.

Which companies overlap with BRIM Biotechnology Inc.'s portfolio?

Top competitors by shared drug class: Aldeyra Therapeutics, Inc., BioCis Pharma Ltd.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/brim-biotechnology-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

BRIM Biotechnology Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BRIM Biotechnology Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 4 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
BRM421 Ophthalmic Solution	BRM421 Ophthalmic Solution	phase 3			Ophthalmology

Therapeutic area mix

Ophthalmology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Aldeyra Therapeutics, Inc. · 1 shared drug class
BioCis Pharma Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for BRIM Biotechnology Inc.:

Cite this brief

Drug Landscape (2026). BRIM Biotechnology Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/brim-biotechnology-inc. Accessed 2026-05-16.